Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.21.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents [note 5] $ 29,637 $ 35,853
Prepaid expenses and other assets 802 1,122
Total current assets 30,439 36,975
Property and equipment, net 33 42
Right-of-use assets [note 7] 108 146
Other assets and restricted cash [note 5] 239 237
License agreement [note 3 and 4] 1,809 1,864
Goodwill [note 4] 1,034 1,034
Total assets 33,662 40,298
Current liabilities:    
Accounts payable 585 332
Accrued liabilities other 211 584
Accrued clinical liabilities 2,130 453
Accrued compensation 522 1,474
Current portion of long-term obligations [note 7] 67 92
Total current liabilities 3,515 2,935
Long-term obligations [note 7] 59 77
Total liabilities 3,574 3,012
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 6,149,917 issued and outstanding at March 31, 2021 and 6,111,735 issued and outstanding at December 31, 2020, respectively. 76 76
Additional paid-in capital 98,441 97,640
Accumulated deficit (68,433) (60,434)
Accumulated other comprehensive income 4 4
Total stockholders' equity 30,088 37,286
Total liabilities and stockholders' equity 33,662 40,298
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value